Clinical trials: Patient With Colorectal Cancer
Colorectal Cancer, Sarcopenia
Predictive Effect of Abdominal Fat and Muscle Area Calculated Based on Abdominal CT on Colorectal Cancer Patients
This study aims to create a clinical prediction model. Abdominal fat and muscle area also play an important role in the prediction of surgical outcomes in colorectal cancer.
- Conditions
- Colorectal Cancer, Sarcopenia, Obesity and Overweight
- Trial name
- NCT06614699
- Testing
- abdominal fat and muscle area
- Where
- 3 sites in China
- Volunteers
- 8,000 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Colorectal Cancer Metastatic
MGD007 Combined With MGA012 in Relapsed/Refractory Metastatic Colorectal Cancer
The primary goal of this study is to characterize the safety, tolerability, and maximum tolerated dose (MTD) of MGD007 when combined with MGA012.
- Trial name
- NCT03531632
- Testing
- MGD007 + MGA012
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- MacroGenics
Colorectal Neoplasms
Prophylactic or Preemptive Entecavir in Patients With Colorectal Cancer Who Are Inactive Hepatitis B Carriers
There has been no report on whether the patients with colorectal cancer who are also inactive Hepatitis B Carriers should receive Prophylactic Use or preemptive Use of an Anti-viral Drug Entecavir.
- Trial name
- NCT02777814
- Testing
- Entecavir
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Colorectal Carcinoma (CRC), Endometrial Carcinoma (EC)
Pilot Window of Opportunity Trial (POET)
The proposed clinical trial with TPST-1495 can help people with two types of cancer, Endometrial Cancer (EC) and Colorectal Carcinoma (CRC), who need surgery.
- Trial name
- NCT06129604
- Testing
- TPST-1495
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Oklahoma
Metastatic Colorectal Cancer
Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors
The primary purpose of the phase Ib is to estimate the MTD/RPD2 and of the phase II is to assess the anti-tumor activity of MEK162 in combination with panitumumab.
- Trial name
- NCT01927341
- Testing
- MEK162, Panitumumab
- Where
- 8 sites in United States, Belgium and 5 more
- Volunteers
- 53 people
- Sponsor
- Pfizer
Colorectal Cancer
Anthocyanin-Rich Berry Supplementation in Patients With Colorectal Cancer
This prospective, open-label interventional study evaluated the effects of short-term supplementation with an anthocyanin-rich freeze-dried black raspberry and strawberry preparation in patients undergoing treatment for…
- Trial name
- NCT07819539
- Testing
- Anthocyanin-Rich Freeze-Dried Berry Supplement
- Where
- Poland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Jagiellonian University
Colorectal Cancer
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer
RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00280176
- Testing
- bortezomib, fluorouracil, radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 11 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Colorectal Cancer, Fatigue
UNTIRE: Cancer-related Fatigue With Digital Treatment
This research is being done to find out if using a smartphone app as digital treatment to reduce Cancer Related Fatigue is feasible and easy to use.
- Trial name
- NCT05584540
- Testing
- UNTIRE App
- Where
- United States
- Sponsor
- Dana-Farber Cancer Institute
Metastatic Colorectal Cancer
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
This include two parts, part 1 is a dose optimizing study and part 2 is a randomized, controlled study.
- Trial name
- NCT05130021
- Testing
- MAX-40279-01, regorafenib
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Maxinovel Pty., Ltd.
Colorectal Cancer
A Phase I/II Study for the Safety and Efficacy of Panitumumab in Combination With TAS-102 for Patients With Colorectal Cancer
The purpose of this study is to evaluate the combination of panitumumab and Triflridine/Tipiracil (FTD/TPI; TAS-102) in patients with RAS wild-type metastatic colorectal cancer (CRC) refractory to standard chemotherapy…
- Trial name
- APOLLON (NCT02613221)
- Testing
- Panitumumab + TAS-102
- Where
- 32 sites in Japan
- Volunteers
- 56 people
- Sponsor
- Takeda
Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma
Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers
This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic).
- Conditions
- Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Carcinoma, Stage IV Gastric Cancer, Stage IV Adenocarcinoma of the Gastroesophageal Junction
- Trial name
- NCT04221893
- Testing
- Radiation Therapy (RT)
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
Metastatic Colorectal Cancer
Panitumumab Plus FOLFIRI in First-line Treatment of Metastatic Colorectal Cancer
To estimate the effect of KRAS mutation status (Wild-type versus Mutant) on objective response rate and other measures of efficacy for patients treated with panitumumab in combination with a chemotherapy regimen of irinotecan…
- Trial name
- NCT00508404
- Testing
- Panitumumab, FOLFIRI
- Volunteers
- 154 people
- Sponsor
- Amgen
Colorectal Adenocarcinoma, Colorectal Carcinoma Metastatic in the Lung
Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases
This phase II trial studies how well chemotherapy and/or metastasectomy work in treating patients with colorectal adenocarcinoma that has spread to the lungs (metastases).
- Conditions
- Colorectal Adenocarcinoma, Colorectal Carcinoma Metastatic in the Lung, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8
- Trial name
- NCT03599752
- Testing
- Chemotherapy, Metastasectomy
- Where
- 6 sites in United States, Canada
- Volunteers
- 40 people
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)
This Phase 1 study will evaluate the safety and tolerability of [Ga-68]-PNT6555 and [Lu-177]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Esophageal Cancer, Melanoma (Skin)
- Trial name
- NCT05432193
- Testing
- [Ga-68]-PNT6555, [Lu-177]-PNT6555
- Where
- 4 sites in United States, Canada
- Volunteers
- 20 people
- Sponsor
- POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company
Advanced Colorectal Carcinoma, Liver Metastasis Colon Cancer
Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy
Fruquintinib (HMPL-013) is a novel oral small molecule that selectively inhibits vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3 and has demonstrated potent inhibitory effects on multiple human tumor xenografts.
- Trial name
- NCT05406206
- Testing
- Fruquintinib, Hepatic Arterial Infusion Chemotherapy
- Where
- China
- Volunteers
- 27 people
- Sponsor
- Peking University Cancer Hospital & Institute
Colorectal Liver Metastases (CRCLM), Unresectable Colorectal Liver Metastases
Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases
This is a observational, prospective, single arm, proof of concept study to assess safety, feasibility, and potential efficacy of combining Yttrium-90 transarterial radioembolization(TARE) with standard systemic therapy in…
- Trial name
- YRENE (NCT07406126)
- Testing
- Yttrium-90 Radioembolization with standard systemic therapy
- Where
- 5 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Fernando Gómez Muñoz
Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors To evaluate the safety and tolerability of naporafenib administered with trametinib in…
- Trial name
- SEACRAFT-1 (NCT05907304)
- Testing
- Naporafenib, Trametinib
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Erasca, Inc.
Older Patients, Colorectal Cancer
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
The goal of this phase III, open-label, non-inferiority randomized controlled clinical trial is compare upfront dose-reduced chemotherapy with the standard dose chemotherapy in older patients ( ≥70 years) with metastasized…
- Conditions
- Older Patients, Colorectal Cancer, Metastatic Cancer, Candidates for Palliative Chemotherapy
- Trial name
- DOSAGE (NCT06275958)
- Testing
- Doublet Chemotherapy, Standard Dose (100%), Doublet Chemotherapy, Dose-reduced (75%), Monotherapy, Standard Dose (100%)
- Where
- 36 sites in Netherlands
- Volunteers
- 587 people
- Sponsor
- Leiden University Medical Center
Cancer Colorectal
Cetuximab as Salvage Therapy in Patients With Neo Wild-type RAS/RAF Metastatic Colorectal Cancer With Liver Metastases.
The purpose of this study is to investigate the efficacy of cetuximab or cetuximab-irinotecan in patients with neo wild-type colorectal cancer who have been previously treated for metastatic disease.
- Trial name
- CETIDYL (NCT04189055)
- Testing
- Cetuximab, Irinotecan
- Where
- France
- Volunteers
- 72 people
- Sponsor
- Hôpital Franco-Britannique-Fondation Cognacq-Jay
Metastases, Neoplasm, Colorectal Neoplasms
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to "stick", to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon.
- Conditions
- Metastases, Neoplasm, Colorectal Neoplasms, Esophageal Neoplasms, Stomach Neoplasms
- Trial name
- NCT00041808
- Testing
- MTC-DOX for Injection, Chemotherapy
- Where
- 4 sites in United States, Germany
- Volunteers
- 20 people
- Sponsor
- FeRx
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.